Sarilumab Beneficial for Polymyalgia Rheumatica Patients
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 5, 2023 -- For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is efficacious for achieving sustained remission and reducing cumulative glucocorticoid dose, according to a study published in the Oct. 5 issue of the New England Journal of Medicine.
Robert F. Spiera, M.D., from Weill Cornell Medical College in New York City, and colleagues conducted a phase 3 trial in which patients were randomly assigned to receive 52 weeks of a twice-monthly subcutaneous injection of either sarilumab or placebo plus a 14-week prednisone taper (60 and 58 patients, respectively). The primary outcome was sustained remission at 52 weeks.
The researchers found that at week 52, sustained remission occurred in 28 and 10 percent of patients in the sarilumab and placebo groups, respectively. At 52 weeks, the median glucocorticoid dose was significantly lower in the sarilumab group versus placebo group (777 versus 2,044 mg, respectively). Neutropenia, arthralgia, and diarrhea were the most common adverse events with sarilumab versus placebo (15 versus 0 percent; 15 versus 5 percent; and 12 versus 2 percent, respectively). Compared with the placebo group, the sarilumab group reported more treatment-related discontinuations (12 versus 7 percent).
"These findings indicate a glucocorticoid-sparing and remission-maintenance effect of sarilumab," the authors write.
The study was funded by Sanofi and Regeneron Pharmaceuticals, which manufacture sarilumab.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
U-Shaped Link Detected Between Adolescent BMI and Mental Health
FRIDAY, May 17, 2024 -- There is a U-shaped association between adolescent body mass index (BMI) and mental health, according to a study published online May 15 in JAMA...
GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription
WEDNESDAY, May 15, 2024 -- Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a...
Child Maltreatment Linked to Externalizing, Internalizing Behavior
TUESDAY, May 14, 2024 -- Child maltreatment is associated with increases in externalizing and internalizing behaviors, according to a study published online May 14 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.